Alyssa M. Vanderbeek

Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications

Rifaquat Rahman, Geoffrey Fell, Steffen Ventz et al. · Clinical Cancer Research · 2019 · 78 citations

Medicine, Biostatistics, Oncology +14

Quantitative <scp>MRI</scp> Differentiates Electromyography Severity Grades of Denervated Muscle in Neuropathy of the Brachial Plexus

Ek T. Tan, Kenneth Serrano, Pravjit Bhatti et al. · Journal of Magnetic Resonance Imaging · 2022 · 25 citations · Full text

Medicine, Neurology, Neuroscience +17

To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs

Alyssa M. Vanderbeek, Steffen Ventz, Rifaquat Rahman et al. · Neuro-Oncology · 2019 · 21 citations · Full text

Medicine, Biostatistics, Oncology +17

Using Patient-Reported Outcomes in Dose-Finding Oncology Trials: Surveys of Key Stakeholders and the National Cancer Research Institute Consumer Forum

Julia Lai‐Kwon, Alyssa M. Vanderbeek, Anna Minchom et al. · The Oncologist · 2022 · 19 citations · Full text

Pharmacy, Oncology, Clinical Trial Regulation +16

The Retail Outlet Health Kiosk Hypertension Trial (ROKHYT): Pilot Results

Steven Shea, John L.P. Thompson, Joseph E. Schwartz et al. · American Journal of Hypertension · 2021 · 14 citations · Full text

Medicine, Chronic Disease Control, Preventive Medicine +17